Advertisement

Research Article Free access | 10.1172/JCI1140

CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties.

E Conseiller, L Debussche, D Landais, C Venot, M Maratrat, V Sierra, B Tocque, and L Bracco

Gene Medicine Department, Rhône-Poulenc Rorer SA, 94403 Vitry sur Seine Cedex, France.

Find articles by Conseiller, E. in: JCI | PubMed | Google Scholar

Gene Medicine Department, Rhône-Poulenc Rorer SA, 94403 Vitry sur Seine Cedex, France.

Find articles by Debussche, L. in: JCI | PubMed | Google Scholar

Gene Medicine Department, Rhône-Poulenc Rorer SA, 94403 Vitry sur Seine Cedex, France.

Find articles by Landais, D. in: JCI | PubMed | Google Scholar

Gene Medicine Department, Rhône-Poulenc Rorer SA, 94403 Vitry sur Seine Cedex, France.

Find articles by Venot, C. in: JCI | PubMed | Google Scholar

Gene Medicine Department, Rhône-Poulenc Rorer SA, 94403 Vitry sur Seine Cedex, France.

Find articles by Maratrat, M. in: JCI | PubMed | Google Scholar

Gene Medicine Department, Rhône-Poulenc Rorer SA, 94403 Vitry sur Seine Cedex, France.

Find articles by Sierra, V. in: JCI | PubMed | Google Scholar

Gene Medicine Department, Rhône-Poulenc Rorer SA, 94403 Vitry sur Seine Cedex, France.

Find articles by Tocque, B. in: JCI | PubMed | Google Scholar

Gene Medicine Department, Rhône-Poulenc Rorer SA, 94403 Vitry sur Seine Cedex, France.

Find articles by Bracco, L. in: JCI | PubMed | Google Scholar

Published January 1, 1998 - More info

Published in Volume 101, Issue 1 on January 1, 1998
J Clin Invest. 1998;101(1):120–127. https://doi.org/10.1172/JCI1140.
© 1998 The American Society for Clinical Investigation
Published January 1, 1998 - Version history
View PDF
Abstract

The clinical potential of the p53 tumor suppressor gene is being evaluated currently for gene therapy of cancer. We have built a variant of wild-type p53, chimeric tumor suppressor 1 (CTS1), in which we have replaced the domains that mediate its inactivation. CTS1 presents some very interesting properties: (a) enhanced transcriptional activity; (b) resistance to the inactivation by oncogenic forms of p53; (c) resistance to the inactivation by MDM2; (d) lower sensitivity to E6-induced degradation; (e) ability to suppress cell growth; and (f ) faster induction of apoptosis. Thus, CTS1 is an improved tumor suppressor and an alternative for the treatment of wild-type p53-resistant human tumors by gene therapy.

Version history
  • Version 1 (January 1, 1998): No description
Advertisement
Advertisement